NASDAQ
35.39USD
-0.59 (-1.64%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.1B
P/E
—
EPS
—
Beta
0.73
52W range
29.7-50.787
Day range
34.40–36.28
Open
35.71
Prev close
35.98
Volume
265.9K
Avg volume
429.4K
Dividend
0.00
IPO
2015-05-07
https://seekingalpha.com/article/4929196-collegium-pharmaceutical-pain-cash-flows-are-funding-an-adhd-re-rating · 8/1/2026+0.80
https://www.zacks.com/commentary/2946828/new-strong-buy-stocks-for-july-6th?cid=CS-STOCKNEWSAPI-FT-zacks_1_rank_additions-2946828 · 7/6/2026+1.00
https://www.zacks.com/stock/news/2946271/collegium-pharmaceutical-stock-gains-12-in-three-months-here-s-why?cid=CS-STOCKNEWSAPI-FT-analyst_blog|price_surge_/_plunge-2946271 · 7/1/2026+0.90
https://www.defenseworld.net/2026/03/21/collegium-pharmaceutical-to-buy-azstarys-for-650m-expanding-adhd-franchise-through-2037.html · 3/21/2026+0.80
https://seekingalpha.com/article/4884371-collegium-pharmaceutical-inc-coll-discusses-acquisition-of-azstarys-to-expand-adhd-portfolio · 3/19/2026
https://www.globenewswire.com/news-release/2025/12/30/3211361/34897/en/Collegium-Announces-the-Closing-of-980-Million-Syndicated-Credit-Facility.html · 12/30/2025+0.80
https://www.zacks.com/stock/news/2807340/are-medical-stocks-lagging-actinium-pharmaceuticals-atnm-this-year?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|yseop_template_1-2807340 · 12/22/2025+0.90
https://www.defenseworld.net/2025/11/28/collegium-pharmaceutical-inc-coll-shares-sold-by-advantage-alpha-capital-partners-lp.html · 11/28/2025-0.20
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
